<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00576836</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00016144 #932</org_study_id>
    <secondary_id>FDA-FD-R-002606</secondary_id>
    <secondary_id>2R01AI047040-11A2</secondary_id>
    <secondary_id>R56 Bridge R01AI4704011A1</secondary_id>
    <secondary_id>5K12HD043494-09</secondary_id>
    <secondary_id>R01AI054843</secondary_id>
    <secondary_id>R01AI047040</secondary_id>
    <secondary_id>3R56AI047040-11A1S1</secondary_id>
    <nct_id>NCT00576836</nct_id>
  </id_info>
  <brief_title>Thymus Transplantation Dose in DiGeorge #932</brief_title>
  <official_title>Dose Study of Thymus Transplantation in DiGeorge Anomaly, IND 9836, #932.1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M. Louise Markert</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Enzyvant Therapeutics GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      One purpose of this study is to determine whether the amount of thymus tissue transplanted
      into DiGeorge anomaly infants has any effect on the immune outcome. Another purpose of this
      study is to determine whether parental parathyroid gland transplantation (in addition to
      thymus transplantation) can help both the immune and the calcium problems in DiGeorge infants
      with hypocalcemia. [Funding Source - FDA OOPD]
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DiGeorge anomaly is a congenital disorder in which infants are born with defects of the
      thymus, heart, and parathyroid gland. Complete DiGeorge Anomaly is usually fatal within the
      first two years of life. This trial evaluates the role of thymus tissue dose in thymus
      transplantation in complete (typical) DiGeorge anomaly infants, and continues safety
      assessments.

      DiGeorge infants who have successful thymus transplants but remain with hypoparathyroidism
      must go to the clinic for frequent calcium levels and to the hospital for calcium infusions;
      these infants are at risk for seizures from low calcium. Approximately ½ of infants with
      profound hypoparathyroidism will develop nephrocalcinosis. This protocol had a parental
      parathyroid transplant arm for complete DiGeorge infants with athymia and profound
      hypoparathyroidism.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Anticipated">June 2027</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Regression analyses used to correlate dose to immunologic parameters: T cell proliferative response; naïve T cells; and T cell variability.</measure>
    <time_frame>1 year post-transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Thymus transplantation efficacy: survival is recorded. Immune reconstitution efficacy: T cell phenotypic and functional parameters are evaluated. This is evaluated in descriptive fashion.</measure>
    <time_frame>Ongoing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parental parathyroid transplantation efficacy: number of subjects who are off calcium and calcitriol supplementation. The time that calcium supplementation needs to be resumed is recorded.</measure>
    <time_frame>1 year post-transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety. Particular attention on oligoclonal T cell development; pulmonary complications; infections; and autoimmune diseases. Dose is correlated with number of subjects who get rashes lasting &gt;1 week with development of wheezing or oxygen requirement.</measure>
    <time_frame>Ongoing - Post-Transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlations between dose and other immune parameters and factors which might affect outcome including HLA matching and thymus donor heart defect. Evaluate whether HLA-DR matching results in increased total CD4 T cell numbers.</measure>
    <time_frame>1 year post-transplantation &amp; ongoing</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>DiGeorge Anomaly</condition>
  <condition>DiGeorge Syndrome</condition>
  <condition>Complete DiGeorge Anomaly</condition>
  <condition>Complete DiGeorge Syndrome</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thymus Tissue for Transplantation With Parathyroid Tissue for Transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thymus Tissue for Transplantation Without Parathyroid Tissue for Transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Thymus Tissue for Transplantation</intervention_name>
    <description>Thymus tissue (from unrelated donor), donor, and donor's mother screened for safety. Thymus transplantation done under general anesthesia. Thymus transplanted into quadriceps. Thymus dose at least 4grams/m2 body surface area (0.2 grams/kg body weight) and not &gt;18 grams/m2 body surface area (1.0 grams/kg body weight). At time of transplant, skin biopsy obtained to look for preexisting T cells. 2-3 months post-transplant allograft biopsy done to evaluate for thymopoiesis &amp; graft rejection. At time of biopsy, skin biopsy done to look for T cell clonal populations. (Allograft biopsy not done if subject medically unstable.) Post-transplant, subjects followed by immune evaluations, using blood samples.</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Parathyroid Tissue for Transplantation</intervention_name>
    <description>Parental parathyroid donors screened for eligibility and transplant safety. If both parents meet eligibility criteria, the parathyroid will be harvested from parent who shares the most HLA alleles with thymus donor. Parathyroid harvest &amp; transplant preferably done at same time as thymus transplant. (If parathyroid transplant cannot be done at same time, then it is done within 3-8 weeks of thymus transplant.) Parathyroid harvest done under general anesthesia. One parathyroid gland is minced &amp; placed in quadriceps muscle; there is no dose in mg. No biopsy done of the parathyroid. Parathyroid donors are monitored as outpatients until recipients' discharge. Recipients' calcium and PTH levels are monitored indefinitely.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Thymus Transplant Inclusion:

          -  Typical Complete DiGeorge Anomaly diagnosis

          -  On 2 separate tests must have &lt; 50 CD3+ T cells/cumm (or &lt; 50 CD3+ T cells/cumm that
             are CD62L+ CD45RA+), or &lt; 5% naïve phenotype T cells

          -  Must have &lt; 20 fold response to PHA (or &lt; 5,000 cpm) on 2 separate tests

          -  Must have 1 of following: 22q11 or 10p13 hemizygosity; hypocalcemia requiring
             replacement; congenital heart defect; CHARGE association or CHD7 mutation; or abnormal
             ears plus mother with diabetes (type I, type II, gestational)

        Exclusion Criteria:

          -  Must not be anticipated to need heart surgery 4 weeks prior or 3 months
             post-transplantation

          -  Present or past lymphadenopathy

          -  Rash associated with T cell infiltration of the dermis and epidermis

          -  Rejection by the surgeon or anesthesiologist as surgical candidate

          -  Lack of sufficient muscle tissue to accept transplant

          -  Prior attempts at immune reconstitution (e.g, BMT or thymus transplantation)

          -  HIV infection

          -  Ventilator Dependence

        Additional Inclusion Criteria for Parathyroid Transplant Recipient:

          -  2 tests showing: intact parathyroid hormone (PTH) &lt; 5 pg/ml when ionized calcium &lt; 1.1
             mmol/L

          -  2 involved parents

        Exclusion for Parathyroid Transplant Recipient:

          -  Parents do not meet enrollment criteria.

          -  Parent(s) decline to be parathyroid donor(s).

        Parental Parathyroid Donor Inclusion:

          -  &gt; 18 years old

          -  Answers all questionnaire items and meets safety screening criteria

          -  Normal serum calcium

          -  Normal PTH function

          -  HLA typing consistent with parentage

          -  Parent chosen for donation will share HLA-DR allele in thymus donor; if not
             applicable, then either parent will be selected (if meet all other criteria).

          -  Must not be on anticoagulation or can come off for donation/transplantation

        Parental Parathyroid Donor Exclusion:

          -  Donor is only living involved parent or caretaker of the recipient

          -  Hypoparathyroidism - low parathyroid hormone (PTH) in presence of low serum calcium
             and high serum phosphate

          -  Hyperparathyroidism (or history of) - elevated PTH in presence of high serum calcium
             and low serum phosphate

          -  History of cancer

          -  Evidence of any of following: HIV-1, HIV-2, HTLV-1, HTLV-2, syphilis, hepatitis B,
             hepatitis C, West Nile virus, or Trypanosoma Cruzi (Chagas disease)

          -  Elevated AST, ALT, alkaline phosphatase &gt; 3 times upper limit of normal

          -  History including receipt of a xenograft or risk factors for SARS, Mad Cow - Disease
             or smallpox. Note: if parent has Mad Cow Disease risk factors (but not active
             disease), parent(s) may give permission for transplantation.

          -  CMV positive urine

          -  Positive CMV IgM antibodies

          -  Positive IgM anti-EBV VCA

          -  On blood thinners and cannot stop for the parathyroid donation

          -  Elevated PT or PTT (&gt; ULN)

          -  Platelets &lt; 100,000

          -  Positive Toxoplasma IgM

          -  The donor will receive a history and physical; may be excluded based on PI's medical
             judgment

          -  Hemoglobin &lt; 9 g/dl

          -  Infectious lesion on head or neck

          -  Goiter on ultrasound

          -  Abnormal fiberoptic laryngoscopy of vocal cords

          -  Pregnancy

          -  Positive HSV IgG is not an exclusion; however, post transplantation prophylaxis is
             needed

          -  Positive VZV IgG is not an exclusion; however, post transplantation prophylaxis is
             needed

          -  Medical concern of otolaryngologist

          -  Concern by medical psychologist or social worker including. Parents are interviewed
             together and separately regarding following areas: medical history; health habits;
             substance use; relationships and support; education/work history; mental
             status/psychological history; readiness for donation.

          -  Questionnaire (safety screening) responses can lead to exclusion.

        Biological Mother of DiGeorge Subject Inclusion Criteria:

          -  Competent to provide consent

          -  Willing to provide blood for testing (No other inclusion/exclusion for mother)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. Louise Markert, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University Medical Center, Pediatrics, Allergy &amp; Immunology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chinn IK, Devlin BH, Li YJ, Markert ML. Long-term tolerance to allogeneic thymus transplants in complete DiGeorge anomaly. Clin Immunol. 2008 Mar;126(3):277-81. Epub 2007 Dec 26.</citation>
    <PMID>18155964</PMID>
  </reference>
  <reference>
    <citation>Markert ML, Sarzotti M, Ozaki DA, Sempowski GD, Rhein ME, Hale LP, Le Deist F, Alexieff MJ, Li J, Hauser ER, Haynes BF, Rice HE, Skinner MA, Mahaffey SM, Jaggers J, Stein LD, Mill MR. Thymus transplantation in complete DiGeorge syndrome: immunologic and safety evaluations in 12 patients. Blood. 2003 Aug 1;102(3):1121-30. Epub 2003 Apr 17.</citation>
    <PMID>12702512</PMID>
  </reference>
  <reference>
    <citation>Chinn IK, Milner JD, Scheinberg P, Douek DC, Markert ML. Thymus transplantation restores the repertoires of forkhead box protein 3 (FoxP3)+ and FoxP3- T cells in complete DiGeorge anomaly. Clin Exp Immunol. 2013 Jul;173(1):140-9. doi: 10.1111/cei.12088.</citation>
    <PMID>23607606</PMID>
  </reference>
  <reference>
    <citation>Chinn IK, Olson JA, Skinner MA, McCarthy EA, Gupton SE, Chen DF, Bonilla FA, Roberts RL, Kanariou MG, Devlin BH, Markert ML. Mechanisms of tolerance to parental parathyroid tissue when combined with human allogeneic thymus transplantation. J Allergy Clin Immunol. 2010 Oct;126(4):814-820.e8. doi: 10.1016/j.jaci.2010.07.016. Epub 2010 Sep 15.</citation>
    <PMID>20832849</PMID>
  </reference>
  <results_reference>
    <citation>Markert ML, Devlin BH, Alexieff MJ, Li J, McCarthy EA, Gupton SE, Chinn IK, Hale LP, Kepler TB, He M, Sarzotti M, Skinner MA, Rice HE, Hoehner JC. Review of 54 patients with complete DiGeorge anomaly enrolled in protocols for thymus transplantation: outcome of 44 consecutive transplants. Blood. 2007 May 15;109(10):4539-47. Epub 2007 Feb 6.</citation>
    <PMID>17284531</PMID>
  </results_reference>
  <results_reference>
    <citation>Markert ML, Devlin BH, McCarthy EA. Thymus transplantation. Clin Immunol. 2010 May;135(2):236-46. doi: 10.1016/j.clim.2010.02.007. Epub 2010 Mar 16. Review.</citation>
    <PMID>20236866</PMID>
  </results_reference>
  <results_reference>
    <citation>Markert ML, Devlin BH, Chinn IK, McCarthy EA, Li YJ. Factors affecting success of thymus transplantation for complete DiGeorge anomaly. Am J Transplant. 2008 Aug;8(8):1729-36. doi: 10.1111/j.1600-6143.2008.02301.x. Epub 2008 Jun 28.</citation>
    <PMID>18557726</PMID>
  </results_reference>
  <results_reference>
    <citation>Markert ML and Devlin BH. Thymic reconstitution (in Rich RR, Shearer WT, Fleischer T, Schroeder HW, Weyand CM, Frew A, eds., Clinical Immunology 3rd edn., Elsevier, Edinburgh) p 1253-1262, 2008.</citation>
  </results_reference>
  <results_reference>
    <citation>Markert ML, Li J, Devlin BH, Hoehner JC, Rice HE, Skinner MA, Li YJ, Hale LP. Use of allograft biopsies to assess thymopoiesis after thymus transplantation. J Immunol. 2008 May 1;180(9):6354-64.</citation>
    <PMID>18424759</PMID>
  </results_reference>
  <results_reference>
    <citation>Hudson LL, Louise Markert M, Devlin BH, Haynes BF, Sempowski GD. Human T cell reconstitution in DiGeorge syndrome and HIV-1 infection. Semin Immunol. 2007 Oct;19(5):297-309. Epub 2007 Nov 26. Review.</citation>
    <PMID>18035553</PMID>
  </results_reference>
  <results_reference>
    <citation>Markert ML, Devlin BH, McCarthy EA, Chinn IK, Hale LP. Thymus Transplantation in Thymus Gland Pathology: Clinical, Diagnostic, and Therapeutic Features. Eds Lavinin C, Moran CA, Morandi U, Schoenhuber R. Springer-Verlag Italia, Milan, 2008, pp 255-267.</citation>
  </results_reference>
  <results_reference>
    <citation>Markert ML, Devlin BH, Chinn IK, McCarthy EA. Thymus transplantation in complete DiGeorge anomaly. Immunol Res. 2009;44(1-3):61-70. doi: 10.1007/s12026-008-8082-5.</citation>
    <PMID>19066739</PMID>
  </results_reference>
  <results_reference>
    <citation>Li B, Li J, Devlin BH, Markert ML. Thymic microenvironment reconstitution after postnatal human thymus transplantation. Clin Immunol. 2011 Sep;140(3):244-59. doi: 10.1016/j.clim.2011.04.004. Epub 2011 Apr 16.</citation>
    <PMID>21565561</PMID>
  </results_reference>
  <results_reference>
    <citation>Ciupe SM, Devlin BH, Markert ML, Kepler TB. Quantification of total T-cell receptor diversity by flow cytometry and spectratyping. BMC Immunol. 2013 Aug 6;14:35. doi: 10.1186/1471-2172-14-35.</citation>
    <PMID>23914737</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2007</study_first_submitted>
  <study_first_submitted_qc>December 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2007</study_first_posted>
  <disposition_first_submitted>September 10, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>September 12, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 14, 2012</disposition_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>M. Louise Markert</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Thymus Transplantation</keyword>
  <keyword>DiGeorge Syndrome</keyword>
  <keyword>DiGeorge Anomaly</keyword>
  <keyword>Athymia</keyword>
  <keyword>Parathyroid Transplantation</keyword>
  <keyword>Hypocalcemia</keyword>
  <keyword>Hypoparathyroidism</keyword>
  <keyword>Low T cell numbers</keyword>
  <keyword>Immunoreconstitution</keyword>
  <keyword>Immunodeficiency</keyword>
  <keyword>Complete DiGeorge</keyword>
  <keyword>Complete DiGeorge Anomaly</keyword>
  <keyword>Typical DiGeorge</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>DiGeorge Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

